請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92299
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉嚞睿 | zh_TW |
dc.contributor.advisor | Je-Ruei Liu | en |
dc.contributor.author | 謝佳霖 | zh_TW |
dc.contributor.author | Chia-Lin Hsieh | en |
dc.date.accessioned | 2024-03-21T16:30:16Z | - |
dc.date.available | 2024-03-22 | - |
dc.date.copyright | 2024-03-21 | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-01-24 | - |
dc.identifier.citation | 許琇涵。2017。具抗病毒能力之乳酸菌株篩選及其特性研究。國立臺灣大學動物科學技術學研究所碩士論文,台北市。
張廖婉萍。2020。克弗爾與其分離菌株抗病毒活性之研究。國立臺灣大學生物科技研究所碩士論文,台北市。 Aboubakr H.A., El-Banna A.A., Youssef M.M., Al-Sohaimy S.A., Goyal S.M., 2014. Antiviral effects of Lactococcus lactis on feline calicivirus, a human norovirus surrogate. Food Environ. Virol., 6 (4), 282-289. Addie D., Belak S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Hosie M.J., Lloret A., Lutz H., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C., 2009. Feline infectious peritonitis. ABCD guidelines on prevention and management. J. Feline Med. Surg. 11 (7) 594-604. Addie D.D., Curran S., Bellini F., Crowe B., Sheehan E., Ukrainchuk L., Decaro N., 2020. Oral Mutian(R)X stopped faecal feline coronavirus shedding by naturally infected cats. Res. Vet. Sci. 130, 222-229. Al Kassaa I., Hober D., Hamze M., Chihib N.E., Drider D., 2014. Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob. Proteins, 6 (3–4), 177-185. Amer A., Siti Suri A., Abdul Rahman O., Mohd H.B., Faruku B., Saeed S., Tengku Azmi T.I., 2012. Isolation and molecular characterization of type I and type II feline coronavirus in Malaysia. Virol. J. 9, 278. Avery, P.R., Hoover, E.A., 2004. Gamma interferon/interleukin 10 balance in tissue lymphocytes correlates with down modulation of mucosal feline immunodeficiency virus infection. J. Virol. 78, 4011–4019. Bae J.Y., Kim J.I., Park S., Yoo K., Kim J.I.H., Joo W., 2018. Effects of Lactobacillus plantarum and Leuconostoc mesenteroides probiotics on human seasonal and avian influenza viruses. J. Microbiol. Biotechnol., 28 (6), 893-901. Bank-Wolf B.R., Stallkamp I., Wiese S., Moritz A. Tekes G., Thiel H.J., 2014. Mutations of 3c and spike protein genes correlate with the occurrence of feline infectious peritonitis Vet. Microbiol. 173 (3-4), 177-188. Barker E.N., Stranieri A., Helps C.R., Porter E.L., Davidson A.D., Day M.J., Knowles T., Kipar A., Tasker S., 2017. Limitations of using feline coronavirus spike protein gene mutations to diagnose feline infectious peritonitis Vet. Res., 48 (1), 60. Benetka V., Kubber-Heiss A., Kolodziejek J., Nowotny N.,Hofmann-Parisot M., Mostl K., 2004. Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis Vet. Microbiol., 99 (1), 31-42. Camero, M., Lanave, G., Catella, C., Lucente, M.S., Sposato, A., Mari, V., Tempesta, M., Martella, V., Buonavoglia, A., 2022. ERDRP-0519 inhibits feline coronavirus in vitro. BMC Vet. Res. 18 (1), 55. Can-Sahna K., Soydal Ataseven V., Pinar D., Oguzoglu T.C., 2007. The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR J. Feline Med. Surg., 9 (5), 369-372. Carasi P., Racedo S.M., Jacquot C., Romanin D.E., Serradell M., Urdaci M., 2015. Impact of kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota. J. Immunol. Res. 2015. Cave T.A., Golder M.C., Simpson J., Addie D.D., 2004. Risk factors for feline coronavirus seropositivity in cats relinquished to a UK rescue charity. J. Feline Med. Surg., 6 (2), 53-58. Chang H.W., Egberink H.F., Halpin R., Spiro D.J., Rottier P.J. 2012. Spike protein fusion peptide and feline coronavirus virulence. Emerg. Infect. Dis., 18 (7), 1089-1095. Chen H.C., Wang S.Y., Chen M.J., 2008. Microbiological study of lactic acid bacteria in kefir grains by culture-dependent and culture-independent methods. Food Microbiol., 25 (3), 492-501. de Barros, B.C.V., de Castro, C.M.O., Pereira, D., Ribeiro, L.G., Junior, J., Casseb, S.M.M., Holanda, G.M., Cruz, A.C.R., Junior, E.C.S., Mascarenhas, J.D.P., 2019. First complete genome sequence of a feline alphacoronavirus 1 strain from Brazil. Microbiol Resour Announc., 8(10), e01535-18 Decaro N., Mari V., Lanave G., Lorusso E., Lucente M.S., Desario C., Colaianni M.L., Elia G., Ferringo F., Alfano F., Buonavoglia C., 2021. Mutation analysis of the spike protein in Italian feline infectious peritonitis virus and feline enteric coronavirus sequences Res. Vet. Sci., 135, 15-19. Dewerchin H.L., Cornelissen E., Nauwynck H.J., 2005. Replication of feline coronaviruses in peripheral blood monocytes. Arch. Virol., 150 (12), 2483-2500. Drechsler Y., Alcaraz A., Bossong F.J., Collisson E.W., Diniz P.P., 2011. Feline coronavirus in multicat environments. Vet. Clin. North Am. Small Anim. Pract., 41 (6), 1133-1169. Dunbar D., Kwok W., Graham E., Armitage A., Irvine R., Johnston P., McDonald M., Montgomery D., Nicolson L., Robertson E., Weir W., Addie D.D., 2019. Diagnosis of non-effusive feline infectious peritonitis by reverse transcriptase quantitative PCR from mesenteric lymph node fine-needle aspirates. J. Feline Med. Surg., 21 (10), 910-921. Evermann J.F., Baumgartener L., Ott R.L., Davis E.V., McKeirnan A.J., 1981. Characterization of a feline infectious peritonitis virus isolate. Vet. Pathol., 18 (2), 256-265. Felten S., Hartmann K., Doerfelt S., Sangl L., Hirschberger J., Matiasek K., 2019. Immunocytochemistry of mesenteric lymph node fine-needle aspirates in the diagnosis of feline infectious peritonitis. J. Vet. Diagn. Invest., 31 (2), 210-216. Fischer Y., Ritz S., Weber K., Sauter-Louis C., Hartmann K., 2011. Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Int. Med. 25, 1270-1276. Fontán M.C.G., Martínez S., Franco I., Carballo J., 2006. Microbiological and chemical changes during the manufacture of Kefir made from cows’ milk, using a commercial starter culture. Int. Dairy J., 16 (7), 762-767 Gao Y., Wang Q., Liang X., Zhang S., Bao D., Zhao H., Li S., Wang K., Hu G, Gao F., 2023. An updated review of feline coronavirus: mind the two biotypes. Virus Res. 236. Giordano A., Stranieri A., Rossi G., Paltrinieri S., 2015. High diagnostic accuracy of the Sysmex XT-2000iV delta total nucleated cells on effusions for feline infectious peritonitis. Vet. Clin. Pathol., 44 (2), 295-302. Giori L., Giordano A., Giudice C., Grieco V., Paltrinieri S., 2011. Performances of different diagnostic tests for feline infectious peritonitis in challenging clinical cases. J. Small Anim. Pract., 52 (3), 152-157. Goitsuka, R., Ohashi, T., Ono, K., Yasukawa, K., Koishibara, Y., Fukui, H., Ohsugi, Y., Hasegawa, A., 1990. IL-6 activity in feline infectious peritonitis. J. Immunol. 144, 2599–2603. Haijema B.J., Volders H., Rottier P.J., 2004. Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J. Virol., 78 (8), 3863-3871. Hellemans A., Acar D.D., Stroobants V.J.E., Theuns S., Desmarets L.M.B., Nauwyn H.J., 2020. A comparative study of techniques used for the diagnosis of effusive feline infectious peritonitis. Vlaams Diergeneeskundig Tijdschrift, 89, 100-110. Hohdatsu, T., Izumiya, Y., Yokoyama, Y., Kida, K., Koyama, H., 1998. Differences in virus receptor for type I and type II feline infectious peritonitis virus. Arch. Virol. 143, 839–850. Hsieh, L.E., Lin, C.N., Su, B.L., Jan, T.R., Chen, C.M., Wang, C.H., Lin, D.S., Lin, C.T., Chueh, L.L., 2010. Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res. 88, 25–30. Isolauri E., Sütas Y., Kankaanpää P., Arvilommi H., Salminen S., 2001. Probiotics: effects on immunity. Am. J. Clin. Nutr., 73 (2), 444s-450s. Jeffery U., Deitz K., Hostetter S., 2012. Positive predictive value of albumin: globulin ratio for feline infectious peritonitis in a mid-western referral hospital population. J. Feline Med. Surg., 14 (12), 903-905. Kanauchi O., Andoh A., AbuBakar S., Yamamoto N., 2018. Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. Curr. Pharm. Des., 24 (6), 710-717 Kipar A., Meli M.L., Baptiste K.E., Bowker L.J., Lutz H., 2010. Sites of feline coronavirus persistence in healthy cats. J. Gen. Virol., 91 (Pt 7),1698-1707. Kitagawa M., Okada M., Sato T., Kanayama K., Sakai T., 2007. A feline case of isolated fourth ventricle with syringomyelia suspected to be related with feline infectious peritonitis. J. Vet. Med. Sci., 69 (7), 759-762 Lewis C.S., Porter E., Matthews D., Kipar A., Tasker S., Helps C.R., Siddell S.G., 2015. Genotyping coronaviruses associated with feline infectious peritonitis. J. Gen. Virol., 96 (Pt 6),1358-1368. Li C., Liu Q., Kong F., Guo D., Zhai J., Su M., Sun D., 2019. Circulation and genetic diversity of Feline coronavirus type I and II from clinically healthy and FIP-suspected cats in China Transbound. Emerg. Dis., 66 (2), 763-775 Licitra B.N., Millet J.K., Regan A.D., Hamilton B.S., Rinaldi V.D., Duhamel G.E., Whittaker G.R., 2013. Mutation in spike protein cleavage site and pathogenesis of feline coronavirus. Emerg. Infect. Dis., 19 (7), 1066-1073 Lin L., Yao D., Wu L., Fan R., Liu Y., Zhou Z., 2022. Molecular epidemiology of type I and II feline coronavirus from cats with suspected feline infectious peritonitis in China between 2019 and 2021. Arch. Virol., 167 (1), 189-194 Lu J., Chen S.A., Khan M.B., Brassard R., Arutyunova E., Lamer T., Vuong W., Fischer C., Young H.S., Vederas J.C., Lemieux M.J., 2022. Crystallization of Feline coronavirus Mpro with GC376 reveals mechanism of inhibition. Front. Chem., 10, 852210 McKay, L.A., Meachem, M., Snead, E., Brannen, T., Mutlow, N., Ruelle, L., Davies, J.L., van der Meer, F., 2020. Prevalence and mutation analysis of the spike protein in feline enteric coronavirus and feline infectious peritonitis detected in household and shelter cats in western Canada. Can. J. Vet. Res. 84 (1), 18–23. Meli M.L., Spiri A.M., Zwicklbauer K., Krentz D., Felten S., Bergmann M., Dorsch R., Matiasek K., Alberer M., Kolberg L., von Both U., Hartmann K., Hofmann-Lehmann R., 2022. Fecal feline coronavirus RNA shedding and spike gene mutations in cats with feline infectious peritonitis treated with GS-441524. Viruses, 14 (5), 1069 Murphy, B.G., Perron M., Murakami E., Bauera K., Park Y., Eckstrand C., Liepnieks M. Pedersen N.C., 2018. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet. Microbiol. 219, 226-233. Niels C. P., Chrissy E., Liu H., Leutenegger C., Murphy B., 2015. Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Vet. Microbiol. 175, 157-166. Nielsen B., Gurakan G.C., Unlu G., 2014. Kefir: a multifaceted fermented dairy product. Probiotics Antimicrob Proteins., 6 (3-4), 123-135. Olaya Galan N.N., Ulloa Rubiano J.C., Velez Reyes F.A., Fernandez Duarte K.P., Salas Cardenas S.P., Gutierrez Fernandez M.F., 2016. In vitro antiviral activity of Lactobacillus casei and Bifidobacterium adolescentis against rotavirus infection monitored by NSP4 protein production. J. Appl. Microbiol., 120 (4), 1041-1051. Ritz S., Egberink H., Hartmann K., 2007. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Int. Med. 21, 1193-1197 Salminen S., Nybom S., Meriluoto J., Collado M.C., Vesterlund S., El-Nezami H., 2010. Interaction of probiotics and pathogens—benefits to human health? Curr. Opin. Biotechnol., 21 (2), 157-167 Soma, T., Saito, N., Kawaguchi, M., Sasai, K., 2018. Feline coronavirus antibody titer in cerebrospinal fluid from cats with neurological signs. J. Vet. Med. Sci. 80 (1), 59–62. Shirato, K., Chang, H.W., Rottier, P.J.M., 2018. Differential susceptibility of macrophages to serotype II feline coronaviruses correlates with differences in the viral spike protein. Virus Res. 255, 14–23. Tekes G and Thiel H.-J., 2016. Feline Coronaviruses: Pathogenesis of Feline Infectious Peritonitis. Adv. Virus Res., 96, 193-218 Vinderola G., Perdigon G., Duarte J., Thangavel D., Farnworth E., Matar C., 2006. Effects of kefir fractions on innate immunity Immunobiology., 211 (3), 149-156. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92299 | - |
dc.description.abstract | 貓傳染性腹膜炎(feline infectious peritonitis, FIP)是貓最重要的傳染病之一,由貓傳染性腹膜炎病毒(feline infectious peritonitis virus, FIPV)引起,FIPV是貓冠狀病毒(feline coronavirus, FCoV)的高毒力突變體。 FIP 的死亡率接近 100%,但目前尚無有效治療方法。 克菲爾是一種發酵乳飲料,由複雜的微生物群組成,是多種乳酸菌 (lactic acid bacteria, LAB) 的共生組合。 這些 LAB 菌株可以調節免疫系統以抑制病毒感染。 LAB 的抗病毒機制涉及直接與病毒相互作用、產生抗病毒相關分子和對於免疫系統的調節。 本研究的目的是建立體外模型,研究乳酸菌在 felis catus whole fetus-4 (fcwf-4) 細胞中對 FIPV 的抗病毒潛力。
從克菲爾中分離出 29 株 LAB 菌株,並研究這些菌株胞內萃取物對 fcwf-4 細胞的細胞毒性。 在細胞毒性試驗中,菌株胞內萃取物添加濃度為50 μg/mL,其中11株菌株無細胞毒性。 以病毒空斑與TCID50測定病毒力價。TCID50結果顯示10-3的FIPV病毒液使fcwf-4細胞活力低於50%,病毒空斑測定之病毒力價為4 x 104 PFU/mL。後續實驗將以MOI=0.06進行感染。 透過檢測LAB 菌株細胞內萃取物的抗 FIPV 活性。 我們發現YPK14和YPK25菌株在預處理試驗中顯示出抗FIPV能力且下調tumor necrosis factor-alpha (TNF-α)and interleukin-6 (IL-6)和FIPV-N基因表現,YPK26菌株在感染後試驗中顯示出抗FIPV能力且上調IL-10基因表現,而YPK6菌株在競爭試驗中顯示出抗FIPV能力且上調interferon-stimulated gene 15 (ISG15)基因表現。 這些 LAB 菌株透過 16S rDNA 和 rpoA 定序鑑定為Lentilactobacillus kefiri和Leuconostoc mesenteroides subsp. mesenteroides。 此外,也研究了乳酸菌菌株的益生菌特性,包括抗病原菌活性、對酸、膽鹽的耐受性和抗生素敏感性。 結果表明,YPK6、YPK 14、YPK25和YPK 26對低pH值具有耐受性。 透過分析 FIPV 感染的 fcwf-4 細胞中抗發炎、促發炎細胞因子和 I 型干擾素相關基因,如Mx1、ISG15、TNF-α、IL-6和 IL-10的表達,闡明了 LAB 菌株的抗病毒活性機制。綜上所述,Lentilactobacillus keferi YPK6、YPK 14、YPK 26 和 Leuconostoc mesenteroides subsp. mesenteroides YPK25 具有抗 FIPV 活性和益生菌潛力。 期能將上述4株菌開發為具有抗病毒活性之益生菌。 | zh_TW |
dc.description.abstract | Feline infectious peritonitis (FIP) is one of the most important infectious diseases in cats with high mortality. It is caused by the feline infectious peritonitis virus (FIPV), a highly virulent mutant form of feline coronavirus (FCoV). The fatality rate of FIP is close to 100% and there are no known effective treatments for cats. Kefir is a fermented milk drink and is composed of complex microbiota, which is a symbiotic association of a variety of lactic acid bacteria (LAB). These LAB strains can modulate the immune system to suppress infections from viruses. The antiviral mechanisms of the LABs involve enhancement of macrophage production, increasing phagocytosis, and boosting production of cytokines. The purpose of the study is to establish an in vitro model to investigate the antiviral potential of LAB for FIPV in felis catus whole fetus-4 (fcwf-4) cell.
A total of 29 LAB strains were isolated from kefir milk and the cytotoxicity of these strains to fcwf-4 cell was investigated. Under the cytotoxicity test, the extract was added at a concentration of 50 μg/mL, and 11 strains had no cytotoxicity. According to TCID50 assay, 10-3 of FIPV dilution ratio caused fcwf-4 cell viability lower than 50%. The results of plaque assay showed that the viral titer used in this study was 4 x 104 PFU/mL. Thus, FIPV infection will be conducted with MOI=0.06. The anti-FIPV activity of the intracellular extracts of LAB strains was examined. We found that YPK14 and YPK25 strains showed anti-FIPV ability and downregulated tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and FIPV-N genes expression in prophylactic model, YPK26 strain showed anti-FIPV ability and upregulated IL-10 gene expression in therapeutic model, while YPK06 strain showed anti-FIPV ability and upregulated interferon-stimulated gene 15 (ISG15) gene expression in direct- inhibitory model. These LAB strains were identified by 16S rDNA and rpoA sequencing as Lentilactobacillus kefiri and Leuconostoc mesenteroides subsp. mesenteroides. Moreover, the probiotic characteristics, including anti-pathogen activity, tolerance of acid, bile salt, and antibiotics sensitivity of the LAB strains were investigated. The results showed that the LAB strains were tolerant to low pH value. The mechanisms of the antiviral activities of the LAB strains were clarified by analysis of the expressions of proinflammatory cytokines and type 1 interferon related genes, such as Mx1, ISG15, TNF-α, IL-6and IL-10 in the FIPV-infected fcwf-4 cells by using qPCR. In conclusion, Lentilactobacillus keferi YPK6, YPK14, YPK26 and Leuconostoc mesenteroides subsp. mesenteroides YPK25 were found to possess anti-FIPV activity and probiotic potential. Thus, they are expected to be used as a probiotic antiviral agent. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-03-21T16:30:16Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2024-03-21T16:30:16Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 目錄
誌謝……………………...………………………………………….…………i 摘要…………………………………………………………………………...ii Abstract………………………...………………………………………….....iv 目錄…………………………………………………………………………..vi 圖目錄……………………...…………………………………………………x 表目錄…………………………………………………...…………………..xii 第一章、文獻探討…………………………………………………...………1 一、貓冠狀病毒簡介………………………………..………………………..1 (一)貓傳染性腹膜炎………………………………..…………………1 (二)歷史沿革………………………………………..…………………2 (三)FCoV種類及地理分佈……………………..………………….…2 (四)基本構造………………………………………..…………………3 (五)感染途徑………………………………………..…………………4 (六)臨床症狀………………………………………..…………………4 (七)疾病造成損失…………………………………..…………………6 (八)疫苗防治………………………………………..…………………6 (九)病毒誘導之免疫反應…………………………..…………………6 (十)預防與治療……………………………………..…………………8 二、益生菌………………………………………………....………………..14 (一)益生菌定義…………………………………..…..………………14 (二)益生菌特性………………………………..………..……………14 (三)常見乳酸菌的種類與特性 ……………..……………………….16 (四)乳酸菌於貓之應用………………………………...…………….17 三、細胞模型(Felis catus whole fetus cell, fcwf-4)………...…………...19 四、干擾素…………………………………………………………………..19 (一)干擾素簡介………………………………………………………..19 (二)I型干擾素之抗病毒機制……………..…………………………..19 (三)I型干擾素誘導之抗病毒防禦…………..………………………..20 五、克菲爾…………………………………………………………………..21 六、研究動機………………………………………………………………..22 第二章、材料與方法………………………………...……………………..23 一、貓傳染性腹膜炎病毒…………………………………………………..23 (一)病毒製備…………………………………………………………23 (二)病毒力價測定……………………………………………………24 二、乳酸菌…………………………………………………………………..25 (一)乳酸菌之活化與保存……………………………………………25 (二)乳酸菌之鑑定……………………………………………………25 1. 16S rDNA、rpoA基因定序……………………………………..25 (三)乳酸菌之預處理…………………………………………………25 (四)蛋白質濃度定量 ………………………………..…………..…...26 三、fcwf-4 細胞…………………………..………………..………………..26 (一)細胞………………………………………………………………26 (二)細胞繼代…………………………………………………………27 (三)冷凍保存細胞株…………………………………………………27 四、胞內萃取物之fcwf-4 細胞毒性分析…………………...……………..27 五、病毒感染之細胞活性分析……………………………………………..28 六、經乳酸菌胞內萃取物處理之fcwf-4細胞之抗病毒活性……...……..29 (一)預防模式…………………………………………………..…….29 (二)治療模式 ………………………………………………………...30 (三)競爭模式 …………………………………………………..…….30 七、Fcwf-4細胞之第一型干擾素下游基因與介白素表現量….………....31 (一)細胞RNA抽取…………………………………………………..31 (二)cDNA製備………………………………………………………32 (三)即時聚合酶連鎖反應……………………………………………32 八、益生菌之特性分析……………………………………………………..33 (一)耐酸測試…………………………………………………………33 (二)耐膽鹽測試………………………………………………………33 (三)抗生素敏感性測試………………………………………………33 (三)抗病原菌測試……………………………………………………34 九、統計分析………………………………………………………………..34 第三章、實驗結果……………………………………………..………….. 38 一、貓傳染性腹膜炎病毒之力價……………………………………….. ...38 二、病毒感染之fcwf-4細胞活性……………………………………... .. ....38 三、經乳酸菌處理之fcwf-4細胞毒性……………………………………..38四、經乳酸菌處理之MARC 145細胞之抗病毒活性…………………..…38 (一)預防模式……………………………………….. ... ... ... ... ... ... ... ... .38 (二)競爭模式…………………………... ... ... ... ... ... ... ...……….……..39 (三)治療模式……………………………………….. ... ... ... ... ... ... ... ...39 五、乳酸菌株胞內萃取物處理與FIPV感染於fcwf-4細胞抗病毒、抗發炎和促發炎基因相關表現量影響…………………………... ...…………….. 39 (一)預防模式………………………………………………...…...…….. .39 (二)競爭模式………………………………………………... ...………...40 (三)治療模式……………………………………………...….…...……...41 六、乳酸菌之菌種鑑定…………………………………...…………... .…..42 七、益生菌之特性……………………………………………….…...……..42 (一)耐酸性……………………………………….. ………………...……42 (二)耐膽鹽能力……………………………………….. ……………...…43 (三)抗生素敏感性………………………………………... ..... …………43 (四)抗病原菌特性………………………………………... ..... ………...43 第四章、討論…………………………………………………….…………75 第五章、結論……………………………………………………………….83 第六章、參考文獻………………………………………………………….84 | - |
dc.language.iso | zh_TW | - |
dc.title | 具抗貓傳染性腹膜炎病毒活性之乳酸菌株篩選 | zh_TW |
dc.title | Screening of lactic acid bacteria strains with anti-feline infectious peritonitis virus activity | en |
dc.type | Thesis | - |
dc.date.schoolyear | 112-1 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 張惠雯;王聖耀;劉啟德 | zh_TW |
dc.contributor.oralexamcommittee | Hui-Wen Chang;Sheng-Yao Wang;Chi-te Liu | en |
dc.subject.keyword | 益生菌,抗病毒,乳酸菌,Feline Infectious Peritonitis virus (FIPV),Leuconostoc mesenteroides subsp. mesenteroides,Lentilactobacillus kefiri, | zh_TW |
dc.subject.keyword | Feline Infectious Peritonitis virus (FIPV),Lentilactobacillus kefiri,Leuconostoc mesenteroides subsp. mesenteroides,anti-viral,lactic acid bacteria (LAB),probiotics, | en |
dc.relation.page | 90 | - |
dc.identifier.doi | 10.6342/NTU202304228 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2024-01-26 | - |
dc.contributor.author-college | 生物資源暨農學院 | - |
dc.contributor.author-dept | 動物科學技術學系 | - |
顯示於系所單位: | 動物科學技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-112-1.pdf 目前未授權公開取用 | 22.33 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。